{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"description":"Participants who displayed a T cell responses against HbSAg following vaccination","groups":[{"description":"Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd for 7 days prior to and 7 days after the vaccine.\n\nLenalidomide: Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd for 7 days prior to and 7 days after the vaccine.","id":"OG000","title":"Lenalidomide"},{"description":"Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.\n\nPlacebo: Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"6 weeks","title":"Quantity of Subjects With a T-cell Response","type":"SECONDARY","unitOfMeasure":"participants"}